Hostname: page-component-784d4fb959-2gr9v Total loading time: 0 Render date: 2025-07-14T20:20:54.612Z Has data issue: false hasContentIssue false

‘Druggability’ of the Per–Arnt–Sim (PAS) domains of human PAS domain kinase, a therapeutic target for metabolic and liver disorders

Published online by Cambridge University Press:  02 February 2024

Shangze Xu
Affiliation:
Chemistry—School of Natural and Environmental Sciences, Newcastle University, Newcastle, UK Newcastle University Centre for Cancer, Newcastle University, Newcastle, UK
Lanyu Fan
Affiliation:
Chemistry—School of Natural and Environmental Sciences, Newcastle University, Newcastle, UK School of Engineering, Newcastle University, Newcastle, UK
Piotr Zaborniak
Affiliation:
Chemistry—School of Natural and Environmental Sciences, Newcastle University, Newcastle, UK
Ruidi Zhu
Affiliation:
Chemistry—School of Natural and Environmental Sciences, Newcastle University, Newcastle, UK
Haoyuan Ji
Affiliation:
Chemistry—School of Natural and Environmental Sciences, Newcastle University, Newcastle, UK
Kate S. Harris
Affiliation:
Chemistry—School of Natural and Environmental Sciences, Newcastle University, Newcastle, UK Translational and Clinical Research Institute, Newcastle University, Newcastle, UK
João V. de Souza
Affiliation:
Chemistry—School of Natural and Environmental Sciences, Newcastle University, Newcastle, UK
Agnieszka K. Bronowska*
Affiliation:
Chemistry—School of Natural and Environmental Sciences, Newcastle University, Newcastle, UK Newcastle University Centre for Cancer, Newcastle University, Newcastle, UK
*
Corresponding author: Agnieszka K. Bronowska; Email: agnieszka.bronowska@ncl.ac.uk
Rights & Permissions [Opens in a new window]

Abstract

Per–Arnt–Sim (PAS) domain kinase (PASK) is a conserved metabolic sensor that modulates the activation of critical proteins involved in liver metabolism and fitness. However, despite its key role in mastering the metabolic regulation, the molecular mechanism of PASK’s activity is ongoing research, and structural information of this important protein is scarce. To investigate this, we integrated structural bioinformatics with state-of-the-art modeling and molecular simulation techniques. Our goals were to address (1) how many regulatory PAS domains PASK is likely to have, (2) how those domains modulate the kinase activity, and (3) how those interactions could be controlled by small molecules. Our results indicated the existence of three N-terminal PAS domains. Solvent mapping and fragment docking identified a consensus set of ‘druggable hot spots’ within all domains, as well as at domain–domain interfaces. Those ‘hot spots’ could be modulated with chemically diverse small molecular probes, which may serve as a starting point for rationally designed therapeutics modulating these specific sites. Our results identified a plausible mechanism of autoinhibition of kinase activity, suggesting that all three putative PAS domains may be required. Future work will focus on validation of the predicted PASK models and development of small-molecule inhibitors of PASK by targeting its ‘druggable hot spots’.

Information

Type
Research Article
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2025. Published by Cambridge University Press

Introduction

The protein kinase with Per–Arnt–Sim (PAS) domains (PASK) is a highly conserved serine/threonine kinase containing N-terminal PAS domains and a C-terminal kinase domain. It acts as a nutrient and energy sensor (Hurtado-Carneiro et al., Reference Hurtado-Carneiro, Roncero, Egger, Wenger, Blazquez, Sanz and Alvarez2014, Reference Hurtado-Carneiro, Pérez-García, Alvarez and Sanz2020) and can also respond to intracellular redox state, light, and oxygen (Dongil et al., Reference Dongil, Pérez-García, Hurtado-Carneiro, Herrero-De-Dios, Blazquez, Alvarez and Sanz2018; Pérez-García et al., Reference Pérez-García, Hurtado-Carneiro, Herrero-De-Dios, Dongil, García-Mauriño, Sánchez, Sanz and Álvarez2021; Hurtado-Carneiro et al., Reference Hurtado-Carneiro, Dongil, Pérez-García, Álvarez and Sanz2021). In mammals, PASK senses nutritional status and contributes to the regulation of glucose homeostasis, energy metabolism, and oxidative stress (Hurtado-Carneiro et al., Reference Hurtado-Carneiro, Dongil, Pérez-García, Álvarez and Sanz2021). PASK regulates glucagon and insulin secretion and is also a critical signaling regulator of the AMPK and mTOR pathways in the liver (Zhang et al., Reference Zhang, Zhang, Wang, Liu, Liu and Li2015). In addition, PASK involvement in protein translation, cell differentiation processes, and epigenetic regulation has recently been described (Kikani et al., Reference Kikani, Wu, Fogarty, Kang, Dephoure, Gygi, Sabatini and Rutter2019). Collectively, these make PASK an attractive therapeutic target, which has been recently validated for conditions such as non-alcoholic steatohepatitis and liver fibrosis (Zhang et al., Reference Zhang, Zhang, Wu, Liu, Gu, Zhu, Wang, Liu and Li2015; Swiatek et al., Reference Swiatek, Parnell, Nickols, Scharschmidt and Rutter2020).

Despite its evolutionary conservation and established role in coordination between cellular metabolism, oxidative stress, and metabolic demand, the molecular mechanism underlying PASK regulation remains ongoing research (Hurtado-Carneiro et al., Reference Hurtado-Carneiro, Pérez-García, Alvarez and Sanz2020). The crystal structure of the kinase domain of human PASK shows that this domain adopts an active conformation and has catalytic activity in the absence of activation loop phosphorylation (Kikani et al., Reference Kikani, Antonysamy, Bonanno, Romero, Zhang, Russell, Gheyi, Iizuka, Emtage, Sauder, Turk, Burley and Rutter2010). It has been therefore suggested that the kinase domain of PASK is autoinhibited by one of its N-terminal PAS domains. The current understanding of PASK activation is that under standard conditions, PASK remains autoinhibited, and the interaction between certain small molecules (such as nutrients or metabolites) and the PAS domain terminates the PASK’s autoinhibited state by unblocking the kinase domain (Figure 1). This may lead to subsequent phosphorylation of PASK’s substrates and regulate their downstream effectors (Hurtado-Carneiro et al., Reference Hurtado-Carneiro, Dongil, Pérez-García, Álvarez and Sanz2021).

Figure 1. The current proposed model of PASK activation. Putative PAS domains of human PASK kinase are presented as circles (blue, aqua, and green). The kinase domain is presented as a yellow oval, and the active site where ATP is bound is depicted as a red circle. Intrinsically disordered regions (IDRs) are depicted as springs. (a) Under resting conditions, PASK assumes a closed, autoinhibited state, wherein PAS domains block the active site of the kinase domain. (b) In the presence of small-molecule ligands (e.g., nutrients, metabolites) depicted as purple circles, one of the PAS domains binds to a ligand, causing conformational changes within the domain and affecting its interactions with the kinase domain. (c) This conformational change leads to unblocking of the kinase domain, thus rendering PASK active.

Despite ongoing efforts, the structural biology and precise mechanism of PASK regulation remain poorly understood. Likewise, the endogenous small molecules modulating PASK are still unknown, and the relationship between PASK and oxidative stress requires better understanding. Since PAS domains are structurally conserved, versatile sensor domains reported to detect hypoxia, redox state, and a broad spectrum of chemically diverse small molecules (e.g., metabolites, pollutants, and drugs) (Poch et al., Reference Poch, Villanelo, Henriquez, Kohen, Muñoz and Devoto2019; Arnaiz et al., Reference Arnaiz, Miar, Bridges, Prasad, Hatch, Ebner, Lawrie and Harris2021; Mullard, Reference Mullard2021), it may be speculated that PAS domains of PASK are sensor domains, crucial for the regulation of this kinase.

PAS domains are small (~100 residues) motifs, present in all kingdoms of life (de Souza et al., Reference de Souza, Reznikov, Zhu and Bronowska2019). In eukaryotes, PAS domains are found in several classes of signaling proteins, including transcriptional regulators, transmembrane channels, and kinases (de Souza et al., Reference de Souza, Reznikov, Zhu and Bronowska2019). Despite their primary sequence variability, these domains have a highly conserved three-dimensional structure, with a hydrophobic cavity where small-molecule ligands may bind. In other mammalian PAS domain sensors, such as the aryl hydrocarbon receptor (AhR), such a binding event initiates a conformational change that spreads over all the protein and affects protein regions distal to the binding event. This may have varied results, such as dissociation of the PAS domain from its cognate binding partner (e.g., Hsp90–AhR complex), formation of a new complex (e.g., AhR–ARNT), and activation (e.g., transcription regulator function of AhR, NPAS, and HIF proteins) (Greb-Markiewicz and Kolonko, Reference Greb-Markiewicz and Kolonko2019; Soshilov et al., Reference Soshilov, Motta, Bonati and Denison2020; Janssens and Stove, Reference Janssens and Stove2021).

Amezcua et al. (Reference Amezcua, Harper, Rutter and Gardner2002) studied the conformational changes within the first PAS domain of human PASK by combining structural biology, biophysical, and biochemical techniques. By solving an NMR structure of this domain (PDB code: 1LL8, residues 131–237), they showed that the domain contains two unusually flexible segments. The locations of those segments indicated that these segments might serve as functionally relevant binding interfaces. NMR-based screening of a library containing over 750 small molecules showed that this domain binds a diverse range of small molecules within its binding site. Furthermore, their work showed that the kinase domain of PASK interacted with the first PAS domain, providing the initial direct biophysical observation of protein–protein interactions (PPIs) within PASK. They concluded that the PAS and kinase domains of PASK are functionally and structurally linked, suggesting a regulatory pathway for small organic molecules to modulate the enzymatic activity of PASK. This study provided a robust proof-of-concept for PASK allosteric regulation occurring via PAS domains. However, the N-terminus of PASK is very long (~950 residues), where several PAS domains have been mapped by bioinformatic approaches (Figure 2). Even though the NMR structure of the first PAS domain of human PASK has been solved (Amezcua et al., Reference Amezcua, Harper, Rutter and Gardner2002), the remainder of the N-terminal region of PASK, including the number, location, and potential ‘druggability’ (that is ability to bind small molecules, such as drugs or metabolites) of those elusive PAS domains remains unexplored.

Figure 2. Diagram showing annotation of human PASK domains by different bioinformatics resources. (a) Consensus domain annotation of N-terminal PASK segment by established structural bioinformatics databases: InterPro – blue, TIGR – khaki, SMART – brown, Prosite – lilac, Pfam – bottle green, and CDD – ochre. Kinase domain has been annotated separately and the colors correspond to dark red – InterPro, purple – SMART, aqua – ProSite, and magenta – Pfam. (b) Consensus homologous superfamily: cyan and aqua – protein kinase-like (InterPro); red – PAS superfamily (InterPro) and orange – PYP-like sensor/PAS (InterPro). (c) Predicted 3D structural regions annotated by Genome3D [35]: blue – PHYRE2 [36] model; brown – structural regions detected by DomSerf [37]. (d) Predicted domains annotated by Genome3D: purple (top) – FUGUE SCOP-based classification; dark green – kinase domain reported by PHYRE2; purple (bottom) – FUGUE CATH-based classification; light green – predicted by pDomTHREADER. Two domains with resolved experimental structures are marked by rectangular selection: PAS1 domain – blue, and protein kinase domain – red. Domains PAS2–PD5 are putative, deduced from the consensus between several predictive tools.

In this work, we have combined complementary computational approaches, to address the following questions: (i) how many PAS domains are likely to span the N-terminus of PASK kinase; (ii) what is their overall structure and how flexible are these domains; (iii) can all of these domains bind small-molecule ligands, and what is the chemical nature of those putative ligands; (iv) which of those PAS domains is the most likely to interact with the kinase domain, and could these putative interactions be modulated by small molecules?

First, using several orthogonal bioinformatics methods, we mapped the location of putative PAS domains. Three-dimensional models of those domains were calculated using a combination of homology modeling via Phyre2 (Kelley et al., Reference Kelley, Mezulis, Yates, Wass and Sternberg2015), alongside modeling using AlphaFold (Jumper et al., Reference Jumper, Evans, Pritzel, Green, Figurnov, Ronneberger, Tunyasuvunakool, Bates, Žídek, Potapenko, Bridgland, Meyer, Kohl, Ballard, Cowie, Romera-Paredes, Nikolov, Jain, Adler, Back, Petersen, Reiman, Clancy, Zielinski, Steinegger, Pacholska, Berghammer, Bodenstein, Silver, Vinyals, Senior, Kavukcuoglu, Kohli and Hassabis2021). Next, we assessed the overall stability and quality of those models by all-atom molecular dynamics simulations in explicit water and excluded those models that showed abnormal energetics, had an unusual number of Ramachandran outliers, or unfolded during the simulations. The resulting model indicated an intrinsically disordered N-terminus, three consecutive PAS domains, and a long, partially disordered linker joining PAS domains and the kinase domain of PASK. The models of the first two domains (PASK1 and PASK2) are consistent with structural and published data (Amezcua et al., Reference Amezcua, Harper, Rutter and Gardner2002; Kikani et al., Reference Kikani, Wu, Fogarty, Kang, Dephoure, Gygi, Sabatini and Rutter2019); however, details of the architecture of the third PAS domain require further investigation. Next, we assessed interactions between PAS and kinase domains by protein–protein docking. These results suggest an explanation of how the kinase domain may be activated by small-molecule binding to N-terminal PAS domains. ‘Druggability’ mapping of individual PAS domains, free and bound to the kinase domain, indicated that these PAS domains may be functionally non-redundant and serve as sensors for chemically diverse ligands. Our results also indicate the presence of interfacial ‘druggable’ sites at autoinhibited PASK, which may pave the way for development of new drugs to inhibit PASK via an allosteric mechanism. Finally, our results suggest that metformin, a first-line drug to treat type 2 diabetes (Wang et al., Reference Wang, He, Feng, Cheng, Luo, Tian and Huang2017), may inhibit PASK by acting as a ‘molecular glue’ between the PAS1–PAS2 segment and the kinase domain. This is likely to shed light on metformin’s mechanism of action, which is not fully understood (Agius et al., Reference Agius, Ford and Chachra2020).

Materials and methods

Structural bioinformatics

A collection of orthogonal tools was used to predict, cross-check, and annotate putative PAS domains within the N-terminal portion of human PASK (UniProt ID: Q96RG2). For consensus domain annotations, the following tools were used: Interpro (Blum et al., Reference Blum, Chang, Chuguransky, Grego, Kandasaamy, Mitchell, Nuka, Paysan-Lafosse, Qureshi, Raj, Richardson, Salazar, Williams, Bork, Bridge, Gough, Haft, Letunic, Marchler-Bauer, Mi, Natale, Necci, Orengo, Pandurangan, Rivoire, Sigrist, Sillitoe, Thanki, Thomas, Tosatto, Wu, Bateman and Finn2021), TIGR (Haft et al., Reference Haft, Loftus, Richardson, Yang, Eisen, Paulsen and White2001), SMART (Letunic et al., Reference Letunic, Khedkar and Bork2021), Prosite (Sigrist et al., Reference Sigrist, de Castro, Cerutti, Cuche, Hulo, Bridge, Bougueleret and Xenarios2013), Pfam (Mistry et al., Reference Mistry, Chuguransky, Williams, Qureshi, Salazar, Sonnhammer, Tosatto, Paladin, Raj, Richardson, Finn and Bateman2021), and the conserved domains database (CDD) (Lu et al., Reference Lu, Wang, Chitsaz, Derbyshire, Geer, Gonzales, Gwadz, Hurwitz, Marchler, Song, Thanki, Yamashita, Yang, Zhang, Zheng, Lanczycki and Marchler-Bauer2020) In this work, all alignment parameters used their default parameters. For sequence/structural annotation, Genome3D was employed (Lewis et al., Reference Lewis, Sillitoe, Andreeva, Blundell, Buchan, Chothia, Cozzetto, Dana, Filippis, Gough, Jones, Kelley, Kleywegt, Minneci, Mistry, Murzin, Ochoa-Montaño, Oates, Punta, Rackham, Stahlhacke, Sternberg, Velankar and Orengo2015), using its default parameter. For prediction of putative domains and structured regions within PASK sequence, we used a combination of Phyre2 homology modeling webserver (Kelley et al., Reference Kelley, Mezulis, Yates, Wass and Sternberg2015), DomSerf (Buchan et al., Reference Buchan, Minneci, Nugent, Bryson and Jones2013), FUGUE (Shi et al., Reference Shi, Blundell and Mizuguchi2001), and pDomThreader/PSIPRED (Lobley et al., Reference Lobley, Sadowski and Jones2009). All algorithms for prediction of domains used their default parameters. The outputs were manually curated, analyzed, and integrated into a single comprehensible consensus output.

Molecular modeling

All plausible domains were extracted from the full-length AlphaFold model (AFQ96RG2) generated from the structure available at Uniprot (Uniprot code Q96RG2) and subjected to 10,000 of molecular mechanical energy minimization using Amber99SB-ILDN force field (Lindorff-Larsen et al., Reference Lindorff-Larsen, Piana, Palmo, Maragakis, Klepeis, Dror and Shaw2010) using GROMACS (van der Spoel et al., Reference Van Der Spoel, Lindahl, Hess, Groenhof, Mark and Berendsen2005). Homology models were calculated using Phyre2 (Kelley et al., Reference Kelley, Mezulis, Yates, Wass and Sternberg2015) and Swiss-Model (Waterhouse et al., Reference Waterhouse, Bertoni, Bienert, Studer, Tauriello, Gumienny, Heer, de Beer, Rempfer, Bordoli, Lepore and Schwede2018) using the following templates: PDB code 1LL8 for human PAS1 (sequence similarity = 60%); PDB code 5SY5 (sequence similarity = 30%); for human PAS2; PDB code 4GW9 for human PAS3 (sequence similarity = 29%); and PDB code 6PH4 for PAS4 (sequence similarity = 31%). For the construct consisting of both PAS1 and PAS2, PDB code: 5SY5 was used as a template. These templates were selected using the following criteria: highest sequence similarity between the target and the template and the lowest number of outliers from the Ramachandran plot.

All-atom molecular dynamics simulations

To address structural stability, energetics and intrinsic dynamics of each putative PAS domain within human PAS–kinase, all-atom molecular dynamics (MD) simulations were performed on the following distinct regions of PASK: PAS1 (residues 124–237), PAS2 (238–335), PAS1–PAS2 construct (residues 124–335), PAS3_homm (residues 337–437), PAS3_AF 3 (residues 343–400 and 885–982), and PD4 (residues 485–592).

All simulations were carried out in GROMACS 2016.1 (van der Spoel et al., Reference Van Der Spoel, Lindahl, Hess, Groenhof, Mark and Berendsen2005), using the AMBER99SB-ILDN force field with the TIP3P water model (Lindorff-Larsen et al., Reference Lindorff-Larsen, Piana, Palmo, Maragakis, Klepeis, Dror and Shaw2010). In each simulation, the protein under investigation was placed in a center of a cubic simulation box. The distance between the box edge and the protein was set to 1 nm. The box was filled with solvent (water) and counter-ions (Na+ and Cl) were added to a concentration of 0.1 M to maintain charge neutrality of the simulation unit and to mimic their physiological concentration. Next, molecular mechanical energy minimization was performed first, for 1,000 cycles of steepest descent, and after that, the algorithm was switched to a conjugate gradient. The minimization step size was set to 0.01 nm, and the maximum number of steps performed was 50,000. The energy minimization stopped when the maximum force of the system was lower than 1,000 kJ mol−1 nm−1 using the Verlet cutoff scheme (Verlet, Reference Verlet1967). The particle mesh-Ewald (PME) was set to long-range electrostatic interactions (Darden et al., Reference Darden, York and Pedersen1993), and the short-range electrostatic and van der Waals cutoff was set to 1.0 nm.

Energy-minimized systems were equilibrated, including the following steps: (1) NVT equilibration for 20 ps, with 2 fs time step, wherein the system has been heated and the target temperature was set at 300 K, by using a modified Berendsen thermostat (τ = 0.1 ps) (Berendsen et al., Reference Berendsen, Postma, Van Gunsteren, Dinola and Haak1984). The constraint algorithm used was LINCS (linear constraint solver) for all bonds in the protein (Hess et al., Reference Hess, Bekker, Berendsen and Fraaije1997). The Verlet cutoff scheme was set to 1.0 nm for non-bonded short interaction, and long-range electrostatics were set to PME. (2) NPT equilibration (20 ps), wherein pressure was kept constant at 1 bar by Parrinello–Rahman isotropic coupling (τ = 2.0 ps) to a pressure bath (Parrinello and Rahman, Reference Parrinello and Rahman1981). (1) and (2) included positional restraints on backbone atoms, to prevent unfolding and other possible artifacts of rapid heating and equilibration. (3) 60 ps of NPT equilibration, with no positional restraints. (4) The production MD simulations were performed for 500 ns in triplicates. The coordinates and energies were saved every 10 ps. Collectively, all production simulations amounted to 9 ms.

Data analysis

Analysis of MD production trajectories was performed using GROMACS tools, FTMap webserver (http://ftmap.bu.edu/login.php) (Kozakov et al., Reference Kozakov, Grove, Hall, Bohnuud, Mottarella, Luo, Xia, Beglov and Vajda2015), and MDAnalysis package (Michaud-Agrawal et al., Reference Michaud-Agrawal, Denning, Woolf and Beckstein2011; Gowers et al., Reference Gowers, Linke, Barnoud, Reddy, Melo, Seyler, Dotson, Domanski, Buchoux, Kenney and Beckstein2016). GROMACS tools included RMSD (root-mean-square deviation) calculations to assess the structural stability of the domain of interest, RMSF (root-mean-square fluctuation) calculations to assess the flexibility per-residue, PCA (principal component analysis) to assess low-amplitude correlated motions, and cluster analysis to evaluate heterogeneity of produced molecular ensembles. H-bond calculations was used as a metric of internal stability of the system, and its internal potential energy calculated via gmx energy. For each system, all trajectories were concatenated prior to the cluster analysis (Daura et al., Reference Daura, Gademann, Jaun, Seebach, van Gusteren and Mark1999) and PCA. The outcomes of PCA and cluster analysis, namely top-three clusters, and clusters representative to PC1-PC3, respectively, were subjected to FTMap: a computational mapping server that identifies binding hotspots in proteins (Kozakov et al., 2015) and a widely used tool on which our group has used and tested (Sabanes et al., Reference Sabanes, De Souza and Bronowska2019). Clustering ensemble similarity (CES), a convergence analysis tool from MDAnalysis package (Michaud-Agrawal et al., Reference Michaud-Agrawal, Denning, Woolf and Beckstein2011) was used for assessing the convergence of the systems. We monitored the cluster evolution through time using MDAnalysis alongside RMSD. The tool splits the trajectory into different windows. the CES value was calculated each time a new conformation space is formed by the current window plus the previous windows, and it was compared with the conformation space formed by the entire trajectory. Faster drop of CES value to 0 means the earlier convergence of the trajectory. Results for CES analysis is shown in Supplementary Figure S14.

Protein–protein docking

Protein–protein docking was performed with ClusPro (https://cluspro.bu.edu/). We used rigid docking, as described by Kozakov et al. (Reference Kozakov, Hall, Xia, Porter, Padhorny, Yueh, Beglov and Vajda2017). Fast-Fourier transform (FFT) employed within ClusPro enables the sampling of billions of putative complex conformations (Desta et al., Reference Desta, Porter, Xia, Kozakov and Vajda2020). This makes the algorithm highly suitable for global docking without any a priori information on the structure of the complex. The performance validation of ClusPro is showed in Supplementary Figure S13.

Docking of PAS and kinase domains of human PASK was carried out sequentially. First, we assigned the crystal structure of the kinase domain (PDB code: 3DLS) as the ‘receptor’ and all PAS domains as ‘ligands’ of binary global docking. We used the highest-populated cluster from MD simulation of each PAS domain as a representative ‘ligand’ frame. Two alternative models of PAS3 were considered. Flexible loops and annotated intrinsically disordered regions were excluded from the calculations in order to reduce noise within the generated data. Each docking run consisted of three following stages: (1) rigid body docking by sampling billions of conformations, applying no geometric restraints; (2) root-mean-square deviation (RMSD) based clustering of the 1,000 lowest energy structures generated to find the largest clusters that will represent the most likely models of the complex, and (3) refinement of selected structures using molecular mechanical energy minimization. The rigid body docking step used PIPER, a docking program based on the FFT correlation approach (Kozakov et al., Reference Kozakov, Brenke, Comeau and Vajda2006). In each run, the 10 best-ranking models were visually inspected.

Furthermore, we used the same procedure to dock: PAS1–PAS2 segment to the kinase domain; PAS2 to the PAS1-kinase domain complexes, PAS1 to the PAS2-kinase domain complexes; PAS3 to the PAS1–PAS2-kinase ternary complexes; PAS2 to the PAS1–PAS3-kinase ternary complexes; and PAS1 to the PAS2–PAS3-kinase ternary complexes. To evaluate the propensity of PAS domains binding to each other, we also calculated PAS–PAS2–PAS3 complexes using the same procedure and subsequently used top-five complexes for the binary docking to the kinase domain. Each calculation involving PAS3 domain included two alternative models (AlphaFold and homology). In total, 24,000 complexes were calculated and evaluated. In each run, the 10 best-ranking models were visually inspected.

Next, we selected those models that satisfied the distance requirement of PAS1–PAS2 and PAS2–PAS3 being less than 1.2 nm apart. This is required, as the interdomain PAS1–PAS2 and PAS2–PAS3 linkers are very short. Such an approach yielded 19 models, with different relative orientation of the domains, and different numbers of PAS domains, interacting with the kinase domain simultaneously. Those complexes were energy-minimized, and the three best-ranking models were selected. Out of these, we prioritized the model that matched best the experimental data available

(Amezcua et al., Reference Amezcua, Harper, Rutter and Gardner2002; Kikani et al., Reference Kikani, Wu, Fogarty, Kang, Dephoure, Gygi, Sabatini and Rutter2019).

Small-molecule docking

The MiniFrag library (O’Rreilly et al., Reference O’Rreilly, Cleasby, Davies, Hall, Ludlow, Murray, Tisi and Jhoti2019) containing 80 chemically diverse, drug-like fragments in SDF format (e.g., phenol, 2-bromopyridine, piperazine, pyrrolidin-2-ylmethanol) was obtained from Enamine (www.enamine.net). The following compounds were added to the library: glucose, fructose, n-hexane, cyclohexane, cyclohexanone, glycerol, glycerol-3-phosphate, arginine (side chain), glutamate (side chain), histidine (side chain), lysine (side chain), metformin, dimethyl fumarate, and monomethyl fumarate. The resulting set, denoted as AugMiniFrag, was used in small-molecule docking calculations.

For each PAS domain, mini-ensembles derived by clustering (PCA analysis and RMSD clustering, using 0.35 nm as the cutoff; six distinct conformations), were subjected to the molecular docking procedure using SeeSAR version 11.2 with HYDE scoring function (Reulecke et al., Reference Reulecke, Lange, Albrecht, Klein and Rarey2008). To evaluate potential PPI sites at kinase–PAS interface, we used the best-scoring complex from protein–protein docking, after MM energy minimization. To map the consensus sites, we searched for the binding sites by FTMap and by the volume search tool in SeeSAR. Only those sites that were reported by both tools were considered for docking. For each consensus site, the AugMiniFrag set was docked using non-covalent docking, maximum 200 poses for each fragment, with high clash tolerance selected. Small molecules with calculated binding affinities worse than high μM range (>500 μM) and torsional strains were discarded. The remaining sets were used for mapping of the consensus ‘hot spots’ within each predicted PAS domain and the PAS–kinase complex.

Results and discussion

Annotation of putative PAS domains within human PASK

While the location and three-dimensional structure of the first PAS domain (PAS1; PDB code: 1LL8; residues 131–237) and the kinase domain (PDB code: 3DLS; residues 977–1300) of human PASK are confirmed (Amezcua et al., Reference Amezcua, Harper, Rutter and Gardner2002; Kikani et al., Reference Kikani, Antonysamy, Bonanno, Romero, Zhang, Russell, Gheyi, Iizuka, Emtage, Sauder, Turk, Burley and Rutter2010), the molecular architecture of the region linking those distal domains has been largely unexplored. Due to the length of this sequence, and the presence of intrinsically disordered regions (IDRs) within, the total number of predicted domains reported and their precise location vary depending on the bioinformatics tools employed. For example, domain annotation within InterPro reports only two PAS domains (spanning residues 121–232, corresponding to PAS1, and 335–402, corresponding to PAS3, Figure 2a), while SCOP and CATH-based classification predicts three PAS domains close together, including experimentally confirmed PAS1 (Figure 2d).

We evaluated those predictions by (i) generating 3D models of all predicted segments, and (ii) investigating the stability of those hypothetical domains by subjecting the calculated models to 500 ns all-atom MD simulations (Supplementary Figures S1–S8). Each run was repeated three times, and the structural features, intrinsic dynamics and stability overall were evaluated. For quality control purposes, we subjected the experimentally confirmed PAS1 domain to the same procedure (Supplementary Figure S2).

Prior to MD simulations, we compared our generated models with predictions using AlphaFold (Jumper et al., Reference Jumper, Evans, Pritzel, Green, Figurnov, Ronneberger, Tunyasuvunakool, Bates, Žídek, Potapenko, Bridgland, Meyer, Kohl, Ballard, Cowie, Romera-Paredes, Nikolov, Jain, Adler, Back, Petersen, Reiman, Clancy, Zielinski, Steinegger, Pacholska, Berghammer, Bodenstein, Silver, Vinyals, Senior, Kavukcuoglu, Kohli and Hassabis2021). The AlphaFold model of human PASK consists of three PAS domains and the kinase domain, with PAS1 and the kinase domain matching well with the experimental structures, and the second PAS2 domain matching the model calculated by homology modeling techniques. However, the third PAS domain predicted by AlphaFold consists of two non-consecutive sequence strands (Figure 3a): 354–397, which is part of PAS3 modeled by homology modeling and threading approaches used by Phyre2 (Figure 3b), and residues 885–932, corresponding to the PD5 region, shown in Figure 2. The confidence score assigned to this PAS3 model was low, particularly this non-consecutive region (70 > pLDDT >50). Nevertheless, we have included this model in further analysis by all-atom MD simulations. In addition, AlphaFold did not detect the putative fourth PD4 domain (residues 485–592, Figure 3c) which has been modeled by homology modeling (Figure 3d). Again, we have analyzed this by all-atom MD. Attempts to model PD5 as a standalone domain by homology modeling and threading approaches failed to produce a good quality model.

Figure 3. (a) AlphaFold model of the putative third PAS domain of human PASK. AlphaFold modeled PAS3 as two non-consecutive sequence strands folded in a single globular domain. The N-terminal strand, comprised of residues 343–393, is colored dark green, while the remaining part, comprised of residues 885–932, is colored gold. This latter segment corresponds to the putative domain PD5, highlighted in Figure 2. (b) Homology model of PAS3 domain. Both Swiss-Model and Phyre2 modeled PAS3 as folded from the consecutive sequence strand (residues 343–435, template: 4GW9:D). The RMSD value between AlphaFold PAS3 model and homology model of PAS3 is 14.393 angstroms (Supplementary Figure S15). To make this panel consistent with the AlphaFold model, residues 343–393 of the domain are colored green, while the remaining part (residues 394–435) are colored purple. (c) AlphaFold did not model a putative fourth PAS domain (PD4), representing this region as an unfolded, random coil. The strand (residues 485–592) is colored as a gradient from the N-terminus (blue) to the C-terminus (red). (d) Phyre2 modeled PAS4 as a folded, globular domain, resembling PAS-fold (template: 6PH4). The color scheme used in this panel is the same as in panel c. (e) Root-mean-square deviation (RMSD) plots of four putative PAS domains: PAS1 – blue, PAS2 – red, PAS3 – aqua, and PD4 – purple. (f) Comparison of RMSD calculations for two models of PAS3 domain: calculated by AlphaFold (black) and calculated by Phyre2 (aqua). (g) Representative frames extracted from four domains under investigation; the color scheme is consistent with panels e and f: PAS1 – blue; PAS2 – red; PAS3 (AlphaFold) – black, and PD4 – purple. PAS1–PAS3 remained stable and well-folded over the simulation time, while PD4 partially unfolded.

All-atom MD simulations indicate three PAS domains within human PASK

All initial models of individual domains were subjected to 500 ns unrestrained equilibrium MD simulations. Data analysis showed that, while PD1–PD3 were stable during the simulation time in all replica runs (Figure 3e), PD4 partially unfolded in two out of three replicas (Figure 3g). This is caused mainly by losing its internal polar contacts in favor to the solvent. Analysis of internal potential energies of all individual domains further suggests that PD4 is very unlikely to retain the PAS-like fold calculated by the homology modeling technique (Supplementary Figure S5). PAS3 domain modeled by AlphaFold remained highly stable (Figure 3f), not showing any major conformational changes during the simulation after achieving a stable configuration. PAS3 domain modeled by Phyre2 (homology modeling) remained highly stable in two out of three replicas (Figure 3e and Supplementary Figure S4), achieving a stable configuration during first 50 ns of the simulations. In one of the replicas, major conformational changes within the ‘gatekeeper’ loop occurred, yet without unfolding (Supplementary Figure S4).

To further investigate the exact location, composition, and stability of the PAS3 domain, we also simulated an AlphaFold model, as an alternative to the homology model. The comparison of these two models is shown in Figure 3f. Despite being composed of two non-consecutive sequence strands (Figure 3a) the model retained features of the canonical PAS domain fold, such as the L-loop with the ‘gatekeeper’ tyrosine residue (Y389), and the core comprised of five antiparallel beta-sheets. There was a significant difference between average values for their RMSD (0.2 nm for the AlphaFold model and 0.8 nm for the homology model) from the starting structure. Both models equilibrated fast and reached their stable conformations before 50 ns of MD simulation (Figure 3f). There were several highly fluctuating residues within the AlphaFold model (Supplementary Figure S10), but the fluctuations resulted from non-constrained terminal regions (residues L885–L982 and C343–L400), and those fluctuations are very likely introduced by the simulation setup. However, calculations of the overall number of hydrogen bonds showed that the AlphaFold model was considerably more stabilized by intramolecular H-bonds than the homology model. On average, the analysis showed 75 ± 4 H-bonds in the AlphaFold model, compared to 60 ± 6 H-bonds within the homology model of PAS3. The analysis of potential energies for both models favored the AlphaFold model: −5,000 ± 300 kJ/mol on average, compared with −3,000 ± 400 kJ/mol for the homology model. These results strongly indicate that the existence of a third PAS domain within PASK is very likely, since its prone to fold into a highly energetically favorable conformation with a high number of well-organized internal hydrogen bonds.

The MD simulations of both PAS3 models show that the low-confidence model calculated by AlphaFold, comprised of two non-consecutive sequence strands, is more plausible. Nevertheless, we subjected both PAS3 models to the ‘druggability’ assessment and subsequent further analysis.

To assess the quality of our simulated ensembles and to evaluate the extent of sampling at 500 ns time scale, we compared the simulation results of the PAS1 domain with the ensemble derived from the solution NMR data available for this domain (Amezcua et al., Reference Amezcua, Harper, Rutter and Gardner2002). We found the overall trends observed in both ensembles to be consistent, with Pearson correlations between RMSF calculated from each three MD simulations replicas and NMR ensemble of 0.88 (replica 1), 0.71 (replica 2), and 0.77 (replica 3). Residues from helix F and loop FG (residues 175–200) were highly flexible in both ensembles (Supplementary Figure S2). Residues 185–194 and termini showed the highest root-mean-square fluctuations in our MD simulations at 500 ns time scale. Amezcua et al. (Reference Amezcua, Harper, Rutter and Gardner2002) showed that these residues exhibited elevated values of the spectral density function J(ω) at high frequencies [J(0.87ωH)] and correspondingly decreased values at lower frequencies [Jeff(0)], indicating that these residues are flexible on fast (ps-to-ns) timescale. Residues 175–184 and 195–200, at both ends of the FG loop, showed average J(0.87ωH) and elevated Jeff(0) values, which indicates that these regions undergo conformational changes on a slower (microsecond to millisecond) timescale. Interestingly, PCA analysis of our 500 ns simulations indicates slow, correlated motions within these regions of PAS1 (Supplementary Figure S3). Collectively, this is consistent with available NMR data and validates our methodology.

As the linker connecting PAS1 and PAS2 domains is very short (3–4 residues), a segment containing both domains and the linker was subjected to the same procedure (500 ns MD simulation, followed by PCA and cluster analysis). The results are consistent with the simulations of isolated PAS1 and PAS2 domains (Supplementary Figures S6–S8) and indicate the propensity of those two domains to change their orientation, but not to the ‘collapse’ of PAS1 on PAS2, which could be attributed to a very short linker (Supplementary Figure S9). Furthermore, the intrinsic flexibility of a linker allows domains to re-orientate themselves upon binding to the kinase domain (Figure 4).

Figure 4. The best-ranking model of PAS domains interacting with the kinase domain of PASK. PASK domains are colored as follows: PAS1 – blue; PAS2 – dark green; PAS3 – red, kinase domain – dark gray. Residues S1149, T1161, and T1165, which are autophosphorylated in the activated kinase, are colored red and highlighted as spheres. The region downstream R1267, which contains several phosphorylated serine residues including S1280, S1287, and S1289, is marked by a light gray circle.

Simulations of the PD4 region indicated that this region is not fully unfolded, as suggested by AlphaFold (Figure 3c), and retains a residual fold comprised of three beta-sheets (residues 552–590), resemblant of SH3-like domain structure. However, the biological significance of this putative domain is uncertain and requires further study, e.g., deletion of this region from the recombinant construct and assessment of the protein’s function.

In summary, our approach indicates the presence of two consensus N-terminal PAS domains in addition to the PAS1 domain, which has been experimentally confirmed resolved by the solution NMR (Amezcua et al., Reference Amezcua, Harper, Rutter and Gardner2002). The third PAS domain is likely to be composed of two non-consecutive sequence segments, as suggested by AlphaFold. Nevertheless, an alternative, consecutive model, calculated by homology modeling techniques, seemed to be stable. Both models share common structural features (Figure 3a, b), which can be used in further analysis of interactions between this domain and other domains of PASK. In addition, established models allow for the follow-up experimental work, which may include expressing different protein constructs and evaluating the function of those domains in cell models.

Interactions between PAS and kinase domains

To explore possible interactions between all three PAS domains and the kinase domain within human PASK, we proceeded with the sequential protein–protein docking calculations, as described in ‘Materials and methods’ section. Because of several constraints, such as distances between PAS1–PAS2 and PAS2–PAS3 domains, this approach narrowed down and generated 19 potential models, as shown in supplementary information (Supplementary Figure S11 and Supplementary Table ST1). The models were cross-checked with the docked ternary complexes of three PAS domains (PAS1–PAS3) and poses that ranked highly in both calculations were prioritized for further analysis.

Even though the predicted energy scores are approximate and thus retain only indicative values, and models are highly speculative, the mechanism in which PAS domains are likely to modulate the PASK kinase domain has emerged. The results of protein–protein docking calculations indicate three binding ‘hot spots’ at the surface of the kinase domain, where the PAS domains are likely to bind (Figure 5). Those ‘hot spots’ were recurrent as highly ranked binding sites, retrieved by all docking runs. Structural constraints within PASK, such as very short PAS1–PAS2 linker and short PAS2–PAS3 loop, favored certain complexes over others.

Figure 5. Consensus ‘hot spots’ identified on all three putative PAS domains and the interface between PAS and kinase domains. The following colors were used for each domain: PAS1 – blue; PAS2 – dark green; PAS3 – red; kinase domain – dim gray. For each PAS domain, two orientations are showed: side (a) and top (b). For the hotspots, the following colors were used: PAS1: H1 – bottle green; H2 – aqua; H3 – pink; PAS2: H4 – tan; H5 – cyan; PAS3: H6 – marine blue; H7 – yellow; H8 – electric blue; H9 – dark magenta. Kinase–PAS domains (c): H13 – navy blue; H14 – gold; H15 – turquoise. In panel c), location of probes H3 in PAS1 (pink); H4 in PAS2 (tan), and H9 in PAS3 (dark magenta) are shown for reference. Nomenclature of hotspots is consistent with Supplementary Table ST3.

Our results suggest that all three PAS domains may be involved in interactions with the kinase domain simultaneously (Figure 4). This model is supported by available mutagenesis data on PASK residues regulated by autophosphorylation: S1149, T1161, T1165, S1287, S1289, S1273, S1277, and S1280 (Kikani et al., Reference Kikani, Antonysamy, Bonanno, Romero, Zhang, Russell, Gheyi, Iizuka, Emtage, Sauder, Turk, Burley and Rutter2010). PAS1 interacts with T1161, PAS2 interacts with T1165 and S1149, while PAS3 interacts with residues downstream R1267. This is shown in Figure 4. Residues in PAS domains predicted to be important in maintaining interactions with the kinase domain are listed in Supplementary Table ST2. In future work, we plan to mutate those residues to further validate our model.

Modulation of PASK by small-molecule ligands

A novel crystallographic screening method has been developed and reported recently by O’Rreilly et al. (Reference O’Rreilly, Cleasby, Davies, Hall, Ludlow, Murray, Tisi and Jhoti2019). In this approach, the high-concentration aqueous soaks were made with a chemically diverse and ultra-low-molecular-weight fragment library denoted as ‘MiniFrags’ (heavy atom count 5–7). This allowed the identification of ‘druggable’ sites on proteins of interest. High screening hit rates reflected enhanced sampling of chemical space. MiniFrag screening can represent thus a highly effective method for ‘druggability’ assessment and guiding optimization of fragment-derived lead compounds. Such an approach is applicable for in silico screening. In this work, we tested it by employing fast ensemble docking of an enriched version of the MiniFrag library (AugMiniFrag; 94 compounds). The original MiniFrag library, which contains a set of chemically diverse fragments obtained from Enamine (www.enamine.net), was been augmented by fragments derived from amino acids known to modulate proteins (e.g., arginine), sugars, free fatty acids, and small drug-like molecules (see Section ‘Materials and methods’).

The set was used in molecular docking against all binding sites detected by FTMap and validated by the binding site mapping mode within SeeSAR (www.biosolveit.de). First, we used all individual domains as targets, using ensembles derived from PCA and cluster analysis of MD simulation trajectories as inputs. Next, we probed interfacial pockets, using outputs from MD simulations of the PAS1–PAS2 segment and results of protein–protein docking (PAS–kinase domains) as inputs.

Results are shown in Figure 5 and Supplementary Table ST3. All PAS domains under investigation were found to be ‘druggable’ by small molecules using FTMap and SeeSAR, including both alternative models of PAS3. The major difference between the two models of PAS3 is the nature of the binding site at the inner cavity of the PAS domain: while the binding site within PAS3 predicted by AlphaFold is very hydrophobic (all side chains but Y894, lining the central cavity, are hydrophobic), the model calculated by homology modeling has a more polar binding cavity (residues Y396, S399, N413, R420, Q428, D432, and K473; Supplementary Figure S12), able to bind a broad spectrum of chemically diverse small molecules, including phosphorylated sugars and side chains of free amino acids (Supplementary Table ST3). We suggest that future studies involving mutation of those residues may contribute to validation of the PASK model and further our understanding of its regulation by small molecules.

Inner pockets of PAS1 and PAS2 have a propensity to bind hydrophobic ligands; however, additional sites were detected on those domains, including the interfacial site at the protein–protein interaction (PPI) interface between both domains. Amezcua et al. (Reference Amezcua, Harper, Rutter and Gardner2002) reported nine compounds that bound PAS1 with dissociation constants smaller than 100 μM. Those compounds were hydrophobic in character, containing one or two aromatic rings substituted with polar groups around their peripheries, and separated by a short linker (0–2 heavy atoms). Molecular docking of those six compounds into the central cavity of PAS1 reproduced those measured Kd values well (p-value = 0.0029; Supplementary Figure S16 and Supplementary Table ST4). Furthermore, molecular docking of the enriched MiniFrag set identified two distinct binding sites on PAS1, additional to that central cavity: one of those sites was modulated by simple sugars (Supplementary Table ST3). Collectively, we identified >10 consensus ‘druggable hotspots’ involving all three PAS domains of PASK. Interfacial binding sites were found on each PAS domain of PASK, which may be explored in the development of allosteric inhibitors of PASK in the future.

We inspected the predicted interface between the kinase domain and PAS domains. Three ‘hot spots’ were detected at the interface between PAS and kinase domains, and the site comprised of three domains: PAS1, PAS2, and kinase domain (Figure 5). These two sites were found to bind arginine and metformin. Metformin is a first-line therapy for the treatment of diabetes type 2 due to its robust glucose-lowering effects and well-established safety and tolerability (Diabetes Prevention Program Research Group, 2012). However, its mechanism of action is poorly understood. Its putative mechanisms of action include indirect activation of AMPK, inhibition of cAMP production, modulation of mTOR, blocking the action of glucagon, and activation of TAK1-IKKα/β signaling (Agius et al., Reference Agius, Ford and Chachra2020). However, the main protein target of metformin remains unknown, and metformin’s activity may rely on modulating multiple targets. Since PASK is regulated by the activity of AMPK and mTOR (Hurtado-Carneiro et al., Reference Hurtado-Carneiro, Roncero, Egger, Wenger, Blazquez, Sanz and Alvarez2014), it is plausible that it can be among the targets modulated by metformin, and its direct interactions should be followed up experimentally. If it were determined that PASK is indeed directly modulated by metformin, it would be beneficial to evaluate whether metformin would indeed the kinase as well as PAS domains of PASK, and whether such binding would disrupt the PPI interface, or make the interactions between the domains stronger.

Conclusions

In this work, we present results of an integrative computational study on human PASK kinase, combining structural bioinformatics, molecular modeling, all-atom MD simulations, molecular docking and ‘hot-spot’ mapping. Our results strongly suggest the presence of three consensus N-terminal PAS domains in human PASK kinase. The experimental structure of one of those domains has resolved by solution NMR and two other domains are predicted; future work will focus on experimental confirmation of those domains. All domains are predicted to be ‘druggable’ by small molecules, albeit with different domains likely to be modulated by different classes of ligands. This is likely to contribute to PASK’s role as a versatile metabolic sensor. Predicted binding sites for diverse small molecules include sites within individual PAS domains as well as ‘druggable hot spots’ at domain–domain interaction interfaces. Proposed three-dimensional model of interactions between PAS domains and the kinase domain of PASK fits with experimental data available and consolidates the model of the kinase domain being inhibited by direct interaction with PAS domain; these interactions may be modulated by small molecules. Future work will focus on those small molecules and their binding sites, which may pave the way for future drug discovery in not only liver and metabolic disorders but also other diseases influenced by oxidative stress, such as neurodegenerative disease. Increased understanding of PASK and its modulation by small molecules has the potential to profoundly impact healthcare research.

Open peer review

To view the open peer review materials for this article, please visit http://doi.org/10.1017/qrd.2024.1.

Supplementary material

The supplementary material for this article can be found at http://doi.org/10.1017/qrd.2024.1.

Acknowledgments

We are grateful to Dr S. Kometa (HPC Rocket) and Dr C. Wills (Newcastle University NMR Facility) for their technical assistance.

Author contribution

P.Z. and A.K.B. outlined the problem and conceptualized the study; J.V.d.S., K.S.H., and A.K.B. designed the study; L.F., A.K.B., and J.V.d.S. performed the bioinformatic analysis; R.Z.; H.J., and L.F. carried out the equilibrium atomistic molecular dynamics simulations of PAS1 and PAS2 domains; S.X. and P.Z. carried out the equilibrium atomistic molecular dynamics simulations of PAS3 and PD4 domains; J.V.d.S. and S.X. wrote scripts for data analysis; S.X., L.F., P.Z., R.Z., and H.J. extracted and analyzed data from the simulations; R.Z., H.J., A.K.B., and K.S.H. performed molecular docking calculations; A.K.B. and K.S.H. supervised the study; all authors produced the figures, plots, and supplementary data. J.V.d.S. and A.K.B. wrote the first draft of the manuscript. K.S.H. edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Financial support

This work was funded by a EPSRC Ph.D. studentship to L.F. (EPR51209X1) and EPSRC funding to A.K.B. (EP/S022791/1).

Competing interest

The authors declare no competing interests.

Footnotes

S.X., L.F., P.Z., R.Z., K.S.H., J.V.d.S. and A.K.B. contributed equally to this work.

References

Agius, L, Ford, BE and Chachra, SS (2020) The metformin mechanism on gluconeogenesis and AMPK activation: The metabolite perspective. International Journal of Molecular Sciences 21, 3240.Google Scholar
Amezcua, CA, Harper, SM, Rutter, J and Gardner, KH (2002) Structure and interactions of PAS kinase N-terminal PAS domain: Model for intramolecular kinase regulation. Structure 10, 13491361.Google Scholar
Arnaiz, E, Miar, A, Bridges, E, Prasad, N, Hatch, SB, Ebner, D, Lawrie, CH and Harris, AL (2021) Differential effects of HIF2α antagonist and HIF2α silencing in renal cancer and sensitivity to repurposed drugs. BMC Cancer 21, 896.Google Scholar
Berendsen, HJC, Postma, JPM, Van Gunsteren, WF, Dinola, A and Haak, JR (1984) Molecular dynamics with coupling to an external bath. Journal of Chemical Physics 81, 36843690.Google Scholar
Blum, M, Chang, HY, Chuguransky, S, Grego, T, Kandasaamy, S, Mitchell, A, Nuka, G, Paysan-Lafosse, T, Qureshi, M, Raj, S, Richardson, L, Salazar, GA, Williams, L, Bork, P, Bridge, A, Gough, J, Haft, DH, Letunic, I, Marchler-Bauer, A, Mi, H, Natale, DA, Necci, M, Orengo, CA, Pandurangan, AP, Rivoire, C, Sigrist, CJA, Sillitoe, I, Thanki, N, Thomas, PD, Tosatto, SCE, Wu, CH, Bateman, A and Finn, RD (2021) The InterPro protein families and domains database: 20 years on. Nucleic Acids Research 49, 344354.Google Scholar
Buchan, DW, Minneci, F, Nugent, TC, Bryson, K and Jones, DT (2013) Scalable web services for the PSIPRED protein analysis workbench. Nucleic Acids Research 41, 349357.Google Scholar
Darden, T, York, D and Pedersen, L (1993) Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems. Journal of Chemical Physics 98, 1008910092.Google Scholar
Daura, X, Gademann, K, Jaun, B, Seebach, D, van Gusteren, WF and Mark, AE (1999) Peptide folding: When simulation meets experiment. Angewandte Chemie, International Edition 38, 236240.Google Scholar
de Souza, JV, Reznikov, S, Zhu, R and Bronowska, AK (2019) Druggability assessment of mammalian Per–Arnt–Sim [PAS] domains using computational approaches. MedChemComm 10, 11261137.Google Scholar
Desta, IT, Porter, KA, Xia, B, Kozakov, D and Vajda, S (2020) Performance and its limits in rigid body protein-protein docking. Structure 28, 10711081.e1073.Google Scholar
Diabetes Prevention Program Research Group (2012) Long-term safety, tolerability, and weight loss associated with metformin in the diabetes prevention program outcomes study. Diabetes Care 35, 731737.Google Scholar
Dongil, P, Pérez-García, A, Hurtado-Carneiro, V, Herrero-De-Dios, C, Blazquez, E, Alvarez, E and Sanz, C (2018) PAS kinase deficiency triggers antioxidant mechanisms in the liver. Scientific Reports 8, 1381013810.Google Scholar
Gowers, RJ, Linke, M, Barnoud, J, Reddy, TJE, Melo, MN, Seyler, SL, Dotson, DL, Domanski, J, Buchoux, S, Kenney, IM and Beckstein, O (2016) MDAnalysis: A python package for the rapid analysis of molecular dynamics simulations. Python in Science Conference 15, 98105.Google Scholar
Greb-Markiewicz, B and Kolonko, M (2019) Subcellular localization signals of bHLH-PAS proteins: Their significance, current state of knowledge and future perspectives. International Journal of Molecular Sciences 20, 4746.Google Scholar
Haft, DH, Loftus, BJ, Richardson, DL, Yang, F, Eisen, JA, Paulsen, IT and White, O (2001) TIGRFAMs: A protein family resource for the functional identification of proteins. Nucleic Acids Research 29, 4143.Google Scholar
Hess, B, Bekker, H, Berendsen, HJC and Fraaije, JGEM (1997) LINCS: A linear constraint solver for molecular simulations. Journal of Computational Chemistry 18, 14631472.Google Scholar
Hurtado-Carneiro, V, Dongil, P, Pérez-García, A, Álvarez, E and Sanz, C (2021) Preventing oxidative stress in the liver: An opportunity for GLP-1 and/or PASK. Antioxidants (Basel, Switzerland) 10, 2028.Google Scholar
Hurtado-Carneiro, V, Pérez-García, A, Alvarez, E and Sanz, C (2020) PAS kinase: A nutrient and energy sensor ‘master key’ in the response to fasting/feeding conditions. Frontiers in Endocrinology 11, 594053594053.Google Scholar
Hurtado-Carneiro, V, Roncero, I, Egger, SS, Wenger, RH, Blazquez, E, Sanz, C and Alvarez, E (2014) PAS kinase is a nutrient and energy sensor in hypothalamic areas required for the normal function of AMPK and mTOR/S6K1. Molecular Neurobiology 50, 314326.Google Scholar
Janssens, LK and Stove, CP (2021) Sensing an oxygen sensor: Development and application of activity-based assays directly monitoring HIF heterodimerization. Analytical Chemistry 93, 1446214470.Google Scholar
Jumper, J, Evans, R, Pritzel, A, Green, T, Figurnov, M, Ronneberger, O, Tunyasuvunakool, K, Bates, R, Žídek, A, Potapenko, A, Bridgland, A, Meyer, C, Kohl, SAA, Ballard, AJ, Cowie, A, Romera-Paredes, B, Nikolov, S, Jain, R, Adler, J, Back, T, Petersen, S, Reiman, D, Clancy, E, Zielinski, M, Steinegger, M, Pacholska, M, Berghammer, T, Bodenstein, S, Silver, D, Vinyals, O, Senior, AW, Kavukcuoglu, K, Kohli, P and Hassabis, D (2021) Highly accurate protein structure prediction with AlphaFold. Nature 596, 583589.Google Scholar
Kelley, LA, Mezulis, S, Yates, CM, Wass, MN and Sternberg, MJE (2015) The Phyre2 web portal for protein modeling, prediction and analysis. Nature Protocols 10, 845858.Google Scholar
Kikani, CK, Antonysamy, SA, Bonanno, JB, Romero, R, Zhang, FF, Russell, M, Gheyi, T, Iizuka, M, Emtage, S, Sauder, JM, Turk, BE, Burley, SK and Rutter, J (2010) Structural bases of PAS domain-regulated kinase (PASK) activation in the absence of activation loop phosphorylation. Journal of Biological Chemistry 285, 4103441043.Google Scholar
Kikani, CK, Wu, X, Fogarty, S, Kang, SAW, Dephoure, N, Gygi, SP, Sabatini, DM and Rutter, J (2019) Activation of PASK by mTORC1 is required for the onset of the terminal differentiation program. Proceedings of the National Academy of Sciences of the United States of America 116, 1038210391.Google Scholar
Kozakov, D, Brenke, R, Comeau, SR and Vajda, S (2006) PIPER: An FFT-based protein docking program with pairwise potentials. Proteins: Structure 65, 392406.Google Scholar
Kozakov, D, Grove, LE, Hall, DR, Bohnuud, T, Mottarella, SE, Luo, L, Xia, B, Beglov, D and Vajda, S (2015) The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins. Nature Protocols 10, 733755.Google Scholar
Kozakov, D, Hall, DR, Xia, B, Porter, KA, Padhorny, D, Yueh, C, Beglov, D and Vajda, S (2017) The ClusPro web server for protein–protein docking. Nature Protocols 12, 255278.Google Scholar
Letunic, I, Khedkar, S and Bork, P (2021) SMART: Recent updates, new developments and status in 2020. Nucleic Acids Research 49, 458460.Google Scholar
Lewis, TE, Sillitoe, I, Andreeva, A, Blundell, TL, Buchan, DW, Chothia, C, Cozzetto, D, Dana, JM, Filippis, I, Gough, J, Jones, DT, Kelley, LA, Kleywegt, GJ, Minneci, F, Mistry, J, Murzin, AG, Ochoa-Montaño, B, Oates, ME, Punta, M, Rackham, OJ, Stahlhacke, J, Sternberg, MJ, Velankar, S and Orengo, C (2015) Genome3D: Exploiting structure to help users understand their sequences. Nucleic Acids Research 43, 382386.Google Scholar
Lindorff-Larsen, K, Piana, S, Palmo, K, Maragakis, P, Klepeis, JL, Dror, RO and Shaw, DE (2010) Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins 78, 19501958.Google Scholar
Lobley, A, Sadowski, MI and Jones, DT (2009) pGenTHREADER and pDomTHREADER: New methods for improved protein fold recognition and superfamily discrimination. Bioinformatics 25, 17611767.Google Scholar
Lu, S, Wang, J, Chitsaz, F, Derbyshire, MK, Geer, RC, Gonzales, NR, Gwadz, M, Hurwitz, DI, Marchler, GH, Song, JS, Thanki, N, Yamashita, RA, Yang, M, Zhang, D, Zheng, C, Lanczycki, CJ and Marchler-Bauer, A (2020) CDD/SPARCLE: The conserved domain database in 2020. Nucleic Acids Research 48, 265268.Google Scholar
Michaud-Agrawal, N, Denning, EJ, Woolf, TB and Beckstein, O (2011) MDAnalysis: A toolkit for the analysis of molecular dynamics simulations. Journal of Computational Chemistry 32, 23192327.Google Scholar
Mistry, J, Chuguransky, S, Williams, L, Qureshi, M, Salazar, GA, Sonnhammer, ELL, Tosatto, SCE, Paladin, L, Raj, S, Richardson, LJ, Finn, RD and Bateman, A (2021) Pfam: The protein families database in 2021. Nucleic Acids Research 49, 412419.Google Scholar
Mullard, A (2021) The Nobel prize-winning path from oxygen sensing research to new drugs. Nature Reviews. Drug Discovery 20, 732733.Google Scholar
O’Rreilly, M, Cleasby, A, Davies, TG, Hall, RJ, Ludlow, RF, Murray, CW, Tisi, D and Jhoti, H (2019) Crystallographic screening using ultra-low-molecular-weight ligands to guide drug design. Drug Discovery Today 24, 10811086.Google Scholar
Parrinello, M and Rahman, A (1981) Polymorphic transitions in single crystals: A new molecular dynamics method. Journal of Applied Physics 52, 7182.Google Scholar
Pérez-García, A, Hurtado-Carneiro, V, Herrero-De-Dios, C, Dongil, P, García-Mauriño, JE, Sánchez, MD, Sanz, C and Álvarez, E (2021) Storage and utilization of glycogen by mouse liver during adaptation to nutritional changes are GLP-1 and PASK dependent. Nutrients 13(8), 2552. https://doi.org/10.3390/nu13082552.Google Scholar
Poch, A, Villanelo, F, Henriquez, S, Kohen, P, Muñoz, A, Strauss JF III and Devoto, L (2019) Molecular modelling predicts that 2-methoxyestradiol disrupts HIF function by binding to the PAS-B domain. Steroids 144, 2129.Google Scholar
Reulecke, I, Lange, G, Albrecht, J, Klein, R and Rarey, M (2008) Towards an integrated description of hydrogen bonding and dehydration: Decreasing false positives in virtual screening with the HYDE scoring function. ChemMedChem 3, 885897.Google Scholar
Sabanes, FZ, De Souza, JV and Bronowska, AK (2019) Cosolvent analysis toolkit (CAT): A robust hotspot identification platform for cosolvent simulations of proteins to expand the druggable proteome. Scientific Reports 9, 19118.Google Scholar
Shi, J, Blundell, TL and Mizuguchi, K (2001) FUGUE: Sequence-structure homology recognition using environment-specific substitution tables and structure-dependent gap penalties. Journal of Molecular Biology 310, 243257.Google Scholar
Sigrist, CJ, de Castro, E, Cerutti, L, Cuche, BA, Hulo, N, Bridge, A, Bougueleret, L and Xenarios, I (2013) New and continuing developments at PROSITE. Nucleic Acids Research 41, D344D347.Google Scholar
Soshilov, AA, Motta, S, Bonati, L and Denison, MS (2020) Transitional states in ligand-dependent transformation of the aryl hydrocarbon receptor into its DNA-binding form. International Journal of Molecular Sciences 21, 2474.Google Scholar
Swiatek, W, Parnell, KM, Nickols, GA, Scharschmidt, BF and Rutter, J (2020) Validation of PAS kinase, a regulator of hepatic fatty acid and triglyceride synthesis, as a therapeutic target for nonalcoholic steatohepatitis. Hepatology Communications 4, 696707.Google Scholar
Uniprot-Q96RG2. PAS domain-containing serine/threonine-protein kinase, Homo sapiens (human). Available at https://www.uniprot.org/uniprotkb/Q96RG2/.Google Scholar
Van Der Spoel, D, Lindahl, E, Hess, B, Groenhof, G, Mark, AE and Berendsen, HJC (2005) GROMACS: Fast, flexible, and free. Journal of Computational Chemistry 26, 17011718.Google Scholar
Verlet, L (1967) Computer ‘experiments’ on classical fluids. I. Thermodynamical properties of Lennard-Jones molecules. Physical Review 159, 98103.Google Scholar
Wang, YW, He, SJ, Feng, X, Cheng, J, Luo, YT, Tian, L and Huang, Q (2017) Metformin: A review of its potential indications. Drug Design, Development and Therapy 11, 24212429.Google Scholar
Waterhouse, A, Bertoni, M, Bienert, S, Studer, G, Tauriello, G, Gumienny, R, Heer, FT, de Beer, TAP, Rempfer, C, Bordoli, L, Lepore, R and Schwede, T (2018) SWISS-MODEL: Homology modelling of protein structures and complexes. Nucleic Acids Research 46, W296W303.Google Scholar
Zhang, DD, Zhang, JG, Wang, YZ, Liu, Y, Liu, GL and Li, XY (2015) Per-Arnt-Sim kinase (PASK): An emerging regulator of mammalian glucose and lipid metabolism. Nutrients 7, 74377450.Google Scholar
Zhang, DD, Zhang, JG, Wu, X, Liu, Y, Gu, SY, Zhu, GH, Wang, YZ, Liu, GL and Li, XY (2015) Nuciferine downregulates Per-Arnt-Sim kinase expression during its alleviation of lipogenesis and inflammation on oleic acid-induced hepatic steatosis in HepG2 cells. Frontiers in Pharmacology 6, 238.Google Scholar
Figure 0

Figure 1. The current proposed model of PASK activation. Putative PAS domains of human PASK kinase are presented as circles (blue, aqua, and green). The kinase domain is presented as a yellow oval, and the active site where ATP is bound is depicted as a red circle. Intrinsically disordered regions (IDRs) are depicted as springs. (a) Under resting conditions, PASK assumes a closed, autoinhibited state, wherein PAS domains block the active site of the kinase domain. (b) In the presence of small-molecule ligands (e.g., nutrients, metabolites) depicted as purple circles, one of the PAS domains binds to a ligand, causing conformational changes within the domain and affecting its interactions with the kinase domain. (c) This conformational change leads to unblocking of the kinase domain, thus rendering PASK active.

Figure 1

Figure 2. Diagram showing annotation of human PASK domains by different bioinformatics resources. (a) Consensus domain annotation of N-terminal PASK segment by established structural bioinformatics databases: InterPro – blue, TIGR – khaki, SMART – brown, Prosite – lilac, Pfam – bottle green, and CDD – ochre. Kinase domain has been annotated separately and the colors correspond to dark red – InterPro, purple – SMART, aqua – ProSite, and magenta – Pfam. (b) Consensus homologous superfamily: cyan and aqua – protein kinase-like (InterPro); red – PAS superfamily (InterPro) and orange – PYP-like sensor/PAS (InterPro). (c) Predicted 3D structural regions annotated by Genome3D [35]: blue – PHYRE2 [36] model; brown – structural regions detected by DomSerf [37]. (d) Predicted domains annotated by Genome3D: purple (top) – FUGUE SCOP-based classification; dark green – kinase domain reported by PHYRE2; purple (bottom) – FUGUE CATH-based classification; light green – predicted by pDomTHREADER. Two domains with resolved experimental structures are marked by rectangular selection: PAS1 domain – blue, and protein kinase domain – red. Domains PAS2–PD5 are putative, deduced from the consensus between several predictive tools.

Figure 2

Figure 3. (a) AlphaFold model of the putative third PAS domain of human PASK. AlphaFold modeled PAS3 as two non-consecutive sequence strands folded in a single globular domain. The N-terminal strand, comprised of residues 343–393, is colored dark green, while the remaining part, comprised of residues 885–932, is colored gold. This latter segment corresponds to the putative domain PD5, highlighted in Figure 2. (b) Homology model of PAS3 domain. Both Swiss-Model and Phyre2 modeled PAS3 as folded from the consecutive sequence strand (residues 343–435, template: 4GW9:D). The RMSD value between AlphaFold PAS3 model and homology model of PAS3 is 14.393 angstroms (Supplementary Figure S15). To make this panel consistent with the AlphaFold model, residues 343–393 of the domain are colored green, while the remaining part (residues 394–435) are colored purple. (c) AlphaFold did not model a putative fourth PAS domain (PD4), representing this region as an unfolded, random coil. The strand (residues 485–592) is colored as a gradient from the N-terminus (blue) to the C-terminus (red). (d) Phyre2 modeled PAS4 as a folded, globular domain, resembling PAS-fold (template: 6PH4). The color scheme used in this panel is the same as in panel c. (e) Root-mean-square deviation (RMSD) plots of four putative PAS domains: PAS1 – blue, PAS2 – red, PAS3 – aqua, and PD4 – purple. (f) Comparison of RMSD calculations for two models of PAS3 domain: calculated by AlphaFold (black) and calculated by Phyre2 (aqua). (g) Representative frames extracted from four domains under investigation; the color scheme is consistent with panels e and f: PAS1 – blue; PAS2 – red; PAS3 (AlphaFold) – black, and PD4 – purple. PAS1–PAS3 remained stable and well-folded over the simulation time, while PD4 partially unfolded.

Figure 3

Figure 4. The best-ranking model of PAS domains interacting with the kinase domain of PASK. PASK domains are colored as follows: PAS1 – blue; PAS2 – dark green; PAS3 – red, kinase domain – dark gray. Residues S1149, T1161, and T1165, which are autophosphorylated in the activated kinase, are colored red and highlighted as spheres. The region downstream R1267, which contains several phosphorylated serine residues including S1280, S1287, and S1289, is marked by a light gray circle.

Figure 4

Figure 5. Consensus ‘hot spots’ identified on all three putative PAS domains and the interface between PAS and kinase domains. The following colors were used for each domain: PAS1 – blue; PAS2 – dark green; PAS3 – red; kinase domain – dim gray. For each PAS domain, two orientations are showed: side (a) and top (b). For the hotspots, the following colors were used: PAS1: H1 – bottle green; H2 – aqua; H3 – pink; PAS2: H4 – tan; H5 – cyan; PAS3: H6 – marine blue; H7 – yellow; H8 – electric blue; H9 – dark magenta. Kinase–PAS domains (c): H13 – navy blue; H14 – gold; H15 – turquoise. In panel c), location of probes H3 in PAS1 (pink); H4 in PAS2 (tan), and H9 in PAS3 (dark magenta) are shown for reference. Nomenclature of hotspots is consistent with Supplementary Table ST3.

Supplementary material: File

Xu et al. supplementary material

Xu et al. supplementary material
Download Xu et al. supplementary material(File)
File 2.7 MB

Author comment: ‘Druggability’ of the Per–Arnt–Sim (PAS) domains of human PAS domain kinase, a therapeutic target for metabolic and liver disorders — R0/PR1

Comments

No accompanying comment.

Review: ‘Druggability’ of the Per–Arnt–Sim (PAS) domains of human PAS domain kinase, a therapeutic target for metabolic and liver disorders — R0/PR2

Conflict of interest statement

Reviewer declares none.

Comments

QRD-D-22-00006

The paper describes the application of a sophisticated collection of structural bioinformatic tools and biomolecular simulation methods to the prediction of the structure and ligand-binding characteristics of the human PASK kinase. Though not in itself proving a definitive answer to this question, it provides a rich set of testable hypotheses for further theoretical and experimental studies, via which this might be achieved.

The work seems to have been done to a high standard, the methodologies used are well described and the results are discussed critically. There are just a few areas where I think some improvements are necessary, or would be very worthwhile:

1. For the homology modelling of individual domains, the sequence alignments with the chosen templates and other metrics (e.g. % sequence identity) should be added to the supplementary material.

2. For the protein-protein docking studies, it would be good to show, if possible, that the chosen methodologies have reasonable performance when applied to related systems where the correct answer is known. For example, they could be tested on other examples of kinases with separate regulatory subunits (maybe protein kinase A, but there could be better examples).

3. For the protein-ligand docking studies, the validation of the methodology through the correlation with the results of Amezcua et al. is claimed but not shown - it should be. In addition, it would be good if it can be shown that related molecules that were found by Amezcua et al. to be much weaker binders are also predicted correctly (increasing the confidence that the approach avoids false positives).

4. For the molecular simulations, using RMSD to evidence equilibration is not a reliable approach. Even when an RMSD from an initial conformation has plateaued, the molecule can be undergoing continued and significant conformational change. A much better approach is to use cluster analysis to produce a discretized version of the trajectory, and plot this as a time series. Cluster analysis is mentioned at a few points in the manuscript, but I don’t see any examples of it in the results. A related point is that details of the clustering method should be included.

5. At some point I would like to see a more explicit comparison of the subunit organisation predicted in this study with that predicted by Alphafold. Though Alphafold-derived structures are mentioned at various points this seems to be with regard to structure prediction of individual subunits rather than their relative positioning in the complex as a whole. The Alphafold model has a large amount of low-confidence structure, but does it include anything that might be pointing to where PAS2 and PAS3, in particular, sit?

Review: ‘Druggability’ of the Per–Arnt–Sim (PAS) domains of human PAS domain kinase, a therapeutic target for metabolic and liver disorders — R0/PR3

Conflict of interest statement

Reviewer declares none.

Comments

In this study the authors claim that the molecular mechanism of PASK' activity and the structural information are not well understood. Therefore, they investigate these gaps with molecular modelling and simulation tools. In terms of structural information, the authors were interested to know the number of PAS domains PASK is likely to have. In terms PASK’s activity the authors were interested to know how the discovered domains modulated the kinase activity and how the domains could be potentially controlled by a small molecule.

The authors reported there were three N-terminal PAS domains. By solvent mapping and fragment docking the authors found potential druggable interfaces within the domains. The authors also suggest mention that they were able to identify mechanism of auto-inhibition of kinase activity, that correlated to the presence of all three PAS domains that they identified. Further addressing that in future work they will improve the “model” and develop small-molecule inhibitors of PASK by targeting the druggable hot-spots.

This reviewer finds the work exciting but however has few concerns and confusion regarding the author’s manuscript as listed below.

1. In the abstract, could the authors clarify what they mean by “Future work will focus on validation of this model ...”. The reviewer is primarily confused about model the authors are referring to.

2. In the introduction, could the authors provide a citation for the sentence “Despite its evolutionary conservation... the molecular mechanism underlying PASK regulation remains poorly understood ...”

3. While the authors claim that PASK’s structural information is not well understood (in abstract), later (in introduction) the authors' report “crystal structure of the kinase domain of human PASK shows that this domain adopts an active conformation and has catalytic activity in the absence of activation loop phosphorylation (Kikani et al., 2010).”. These two sentences are in contrast to each other. Therefore, the reviewer requests the authors to revise their abstract.

4. This reviewer also finds the term “AI modelling” in the sentence “Three-dimensional models of those domains were calculated using a combination of homology modelling, threading, and AI modelling by AlphaFold (Jumper et al., 2021)” misleading. The authors simply used a deep learning tool to predict the structure. Furthermore, the authors only cite what they call AI modelling, but does not mention or cite what tools they use for homology modelling and threading. Therefore, the reviewer is requesting for a revision in this sentence.

5. Could the author provide a citation to the mentioned experimental data in the sentence “Such a model is consistent with the experimental data available” and/or elaborate on the type of experimental data and so on.

6. While the authors have explored the interaction of PAS and kinase domains by protein-protein docking, the recent release of AlphaFold-Multimer has shown that it outperforms protein-protein docking by a large margin. Could the author repeat the experiment with AlphaFold-Multimer and carry out similar analysis and also report how they are similar or differ from their results from protein-protein docking?

7. Could the authors cite this “... a first-line drug to treat type 2 diabetes, ...”

8. What parameters were used for AlphaFold? If this the default settings, the authors should mention this in their methods section. Additionally in the introduction the authors mention threading separately however in the methods section no details regarding this was found? Could the authors comment more on why this is the case? Was threading part of the homology modelling procedure of Phyre2? If so then the authors should clarify this. If not, then the authors need to provide additional details.

9. In the structural bioinformatics method section, the author several methods and provide the link to their website. However, the link “http://www.tigr.org/tdb/tgi” report page not found. The authors should double check if the link they provided is the correct link. The reviewer also believe citing the methods paper for these tool maybe enough for readers. Furthermore, could the authors expand this section and explain exactly what tools were used for what as well as the parameters that were set when these tools were used. Was this default or customized? If default, then this needs to be mentioned. If customized then it needs to mentional as well as rationalized. Additionally a schematic of a workflow diagram for this section would make it very clear for readers as to how the authors used these tool. The reviewer strongly suggest in making such schematic.

10. For the sentence “... using the following templates: 1LL8 (PAS1); 5SY5 (PAS2); 4EH0 (PAS3) ...” could the author mention what they mean by PAS1, PAS2, and PAS3? The reviewere is assuming that these are the three domains? The authors need to clarify this. Furthermore, in the sentence mentioned, the authors also need to mention that the code outside the parathesis are PDBID (assuming they are that), as it may not be clear to readers who may not know what these are.

11. In the data analysis section, the authors need to correctly cite FTMap as mentioned in their publication page of their website “http://ftmap.bu.edu/publications.php”.

12. The authors need to mention what type of clustering algorithm they used. If this is gmx cluster then they need to cite the clustering algorithm with “Angew. Chem. Int. Ed. 1999, 38, pp 236-240”.

13. As mentioned before, in the protein-protein docking section, the reviewer is curious to why the authors chose not to use AlphaFold-Multimer. In this way sampling billions of conformations could have been avoided. The reviewer urges the authors to carryout complex structure prediction with AlphaFold-Multimer, carryout all analysis and report on their findings.

14. Could the authors add a sentence as for the line “Flexible loops and annotated ntrinsically disordered regions were excluded from the calculations” as to why this was done?

15. The reviewer suggests all complex structure prediction to be carried out with AlphaFold-Multimer.

16. While the authors mention the usage of Swiss Model in Figure 3b. They do not mention the protocols they used for Swiss Model in their Methods sections. Therefore the reviewer request the authors to revise their Methods section and include the procedures as appropriate.

17. Could the authors provide additional details as to why PD4 partially unfolded?

18. In the Results and Discussion section, the authors mention “H-bond analysis of both models ...”. Could authors elaborate how the H-bond were analyzed. What was used to analyze the H-bond in these trajectories. Details in the methods section and briefly remind readers of what was used in the results and discussion section.

19. Could the authors add more discussion sentences as to why this was the case for the line “AlphaFold model was considerably more stabilised by intramolecular H-bonds than the homology model”?

20. For the sentences “The analysis of potential energies for both models favoured the AlphaFold model: -5000 ± 300 kJ/mol on average, compared with -3000 ± 400 kJ/mol for the homology model. These results strongly indicate that the existence of a third PAS domain within PASK is very likely.”, could the authors clarify further why this indicated the existence of a third PAS domain? Additionally could the authors remind the readers how the potential energy calculation were done?

21. For Fig. S10, could the authors add a few discussion sentence as to why there was high fluctuation for the AlphaFold model around the time 50ns - 65ns but not for the homology model. This is counter intuitive given the report that there were higher number of H-bonds for the AlphaFold model than the homology model. Could author report why this was the case?

22. Could the authors align the AlphaFold model and the homology model and report the structural similarity (RMSD) in Fig. 3a -3b.

23. In Fig. 4, the author talk about experimental data, but it is not clear what these experimental data are. Could the authors please clarify what experimental data they are discussing?

24. While the author used deep learning tool (AlphaFold) to predict the structure of PAS domain, they did not use any such deep learning tool to identify druggable hotspots. The reviewer urges the authors to make use of some of the well known open-source deep learning tools to further validate druggable hotspots within the PAS domains.

25. In the following line “Molecular docking of those nine compounds into the central cavity of PAS1 reproduced those measured Kd values well (data not shown)”, the reviewer is intrigued as to why the correlation of the Kd values were not show and urges the authors to provide additional comments regarding this. Additionally how were the Kd values predicted? The authors need to clarify this.

Overall, this reviewer finds this work very exciting and is looking forward to the changes/revisions requested.

Decision: ‘Druggability’ of the Per–Arnt–Sim (PAS) domains of human PAS domain kinase, a therapeutic target for metabolic and liver disorders — R0/PR4

Comments

No accompanying comment.

Author comment: ‘Druggability’ of the Per–Arnt–Sim (PAS) domains of human PAS domain kinase, a therapeutic target for metabolic and liver disorders — R1/PR5

Comments

Dr Finn Haunch

Quarterly Reviews of Biophysics and QRB Discovery

Re: Manuscript revision

Dear Doctor Haunch,

On behalf of my coworkers and myself, I am submitting the revised version of our manuscript entitled “Druggability” of PAS domains of human PASK kinase, a therapeutic target for metabolic and liver disorders for your consideration for publication in QRB Discovery.

We would like to thank you very much for your patience whilst we address the comments presented by the reviewers. We would like to thank both reviewers for critically assessing our manuscript and for providing some very helpful comments and suggestions. We appreciate such detailed comments, which show they have taken a lot of time and care in assessing our work. We have addressed their suggestions, and all the corrections suggested were applied through the revised version of the manuscript. The specific comments and our responses to these comments are listed in the separate document.

Given the importance of understanding the effects of PASK regulation in health and disease, we believe that this revised contribution is relevant to QRB Discovery’s readership. We gratefully acknowledge the financial support by Engineering and Physical Sciences Research Council (EPSRC; EPR51209X1 and EP/S022791/1) and declare no competing interests. We appreciate your taking the time to consider our manuscript, and we are happy to provide any further clarifications, should they be required.

Yours Sincerely,

Agnieszka K. Bronowska

Decision: ‘Druggability’ of the Per–Arnt–Sim (PAS) domains of human PAS domain kinase, a therapeutic target for metabolic and liver disorders — R1/PR6

Comments

No accompanying comment.